KCNH2 pharmacogenomics summary.
作者信息
Oshiro Connie, Thorn Caroline F, Roden Dan M, Klein Teri E, Altman Russ B
机构信息
Department of Genetics, Stanford University bBioengineering, Stanford University Medical Center, Stanford, California 94305-5120, USA.
出版信息
Pharmacogenet Genomics. 2010 Dec;20(12):775-7. doi: 10.1097/FPC.0b013e3283349e9c.
Abstract
摘要
相似文献
1
KCNH2 pharmacogenomics summary.KCNH2药物基因组学总结。
Pharmacogenet Genomics. 2010 Dec;20(12):775-7. doi: 10.1097/FPC.0b013e3283349e9c.
2
Polymorphisms and atrial fibrillation: sorting the wheat from the chaff.多态性与心房颤动：去伪存真
Eur Heart J. 2008 Apr;29(7):843-5. doi: 10.1093/eurheartj/ehn066. Epub 2008 Feb 28.
3
The non-synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of KCNH2 (HERG).非同义编码的 IKr 通道变体 KCNH2-K897T 与心房颤动相关：基于 KCNH2（HERG）的系统性候选基因分析结果
Eur Heart J. 2008 Apr;29(7):907-14. doi: 10.1093/eurheartj/ehm619. Epub 2008 Jan 25.
4
[KCNQ1, KCNH2, KCNE1 and KCNE2 potassium channels gene variants in sudden manhood death syndrome].[青壮年猝死综合征中KCNQ1、KCNH2、KCNE1和KCNE2钾通道基因变异]
Fa Yi Xue Za Zhi. 2012 Oct;28(5):337-41, 346.
5
LQT5 masquerading as LQT2: a dominant negative effect of KCNE1-D85N rare polymorphism on KCNH2 current.LQT5 伪装为 LQT2：KCNE1-D85N 稀有多态性对 KCNH2 电流的显性负性作用。
Europace. 2011 Oct;13(10):1478-83. doi: 10.1093/europace/eur184. Epub 2011 Jun 28.
6
Congenital long QT syndrome: a case report of LQT2 and LQT13 in a neonate.先天性长QT综合征：1例新生儿LQT2和LQT13病例报告
Europace. 2014 Dec;16(12):1807. doi: 10.1093/europace/euu299.
7
The KCNH2 genetic polymorphism (1956, C>T) is a novel biomarker that is associated with CCB and α,β-ADR blocker response in EH patients in China.KCNH2 基因多态性（1956，C>T）是一种新型生物标志物，与中国 EH 患者的 CCB 和α、β-ADR 阻滞剂反应相关。
PLoS One. 2013 Apr 22;8(4):e61317. doi: 10.1371/journal.pone.0061317. Print 2013.
8
Protective effect of KCNH2 single nucleotide polymorphism K897T in LQTS families and identification of novel KCNQ1 and KCNH2 mutations.KCNH2单核苷酸多态性K897T在长QT综合征家族中的保护作用及新型KCNQ1和KCNH2突变的鉴定
BMC Med Genet. 2008 Sep 23;9:87. doi: 10.1186/1471-2350-9-87.
9
[A novel mutation of the KCNH2 gene in a family with congenital long QT syndrome].一个先天性长QT综合征家族中KCNH2基因的新型突变
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010 Feb;27(1):77-80. doi: 10.3760/cma.j.issn.1003-9406.2010.01.017.
10
Gene symbol: KCNH2.基因符号：KCNH2。
Hum Genet. 2007 Feb;120(6):911.
引用本文的文献
1
Discovering Potential Compounds for Venous Disease Treatment through Virtual Screening and Network Pharmacology Approach.通过虚拟筛选和网络药理学方法发现静脉疾病治疗的潜在化合物。
Molecules. 2023 Dec 5;28(24):7937. doi: 10.3390/molecules28247937.
2
New insights into the genetic predisposition of brucellosis and its effect on the gut and vaginal microbiota in goats.布鲁氏菌病遗传易感性的新见解及其对山羊肠道和阴道微生物群的影响。
Sci Rep. 2023 Nov 16;13(1):20086. doi: 10.1038/s41598-023-46997-x.
3
Modulating the voltage sensor of a cardiac potassium channel shows antiarrhythmic effects.调节心脏钾通道的电压传感器可显示抗心律失常作用。
Proc Natl Acad Sci U S A. 2021 May 18;118(20). doi: 10.1073/pnas.2024215118.
4
Pharmacogenomic Biomarkers and Their Applications in Psychiatry.精神医学中的药物基因组学生物标志物及其应用。
Genes (Basel). 2020 Nov 30;11(12):1445. doi: 10.3390/genes11121445.
5
Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines.多种人体组织和淋巴母细胞系中药物代谢基因的转录组变异
Pharmacogenomics J. 2017 Mar;17(2):137-145. doi: 10.1038/tpj.2015.93. Epub 2016 Feb 9.
6
Addressing phenoconversion: the Achilles' heel of personalized medicine.应对表型转换：个性化医疗的致命弱点。
Br J Clin Pharmacol. 2015 Feb;79(2):222-40. doi: 10.1111/bcp.12441.
7
The KCNH2 genetic polymorphism (1956, C>T) is a novel biomarker that is associated with CCB and α,β-ADR blocker response in EH patients in China.KCNH2 基因多态性（1956，C>T）是一种新型生物标志物，与中国 EH 患者的 CCB 和α、β-ADR 阻滞剂反应相关。
PLoS One. 2013 Apr 22;8(4):e61317. doi: 10.1371/journal.pone.0061317. Print 2013.
8
Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated?应对全球安全问题：非心脏药物致 QT 间期延长风险的应对是否协调一致？
Drug Saf. 2013 Mar;36(3):167-82. doi: 10.1007/s40264-013-0016-z.
9
The importance of being profiled: improving drug candidate safety and efficacy using ion channel profiling.进行特征分析的重要性：利用离子通道特征分析提高候选药物的安全性和有效性。
Front Pharmacol. 2011 Dec 13;2:78. doi: 10.3389/fphar.2011.00078. eCollection 2011.
10
Pharmacogenomics and bioinformatics: PharmGKB.药物基因组学和生物信息学：PharmGKB。
Pharmacogenomics. 2010 Apr;11(4):501-5. doi: 10.2217/pgs.10.15.
本文引用的文献
1
Common variants at ten loci modulate the QT interval duration in the QTSCD Study.在QTSCD研究中，十个基因座的常见变异可调节QT间期持续时间。
Nat Genet. 2009 Apr;41(4):407-14. doi: 10.1038/ng.362. Epub 2009 Mar 22.
2
Common variants at ten loci influence QT interval duration in the QTGEN Study.在QTGEN研究中，十个基因座上的常见变异影响QT间期持续时间。
Nat Genet. 2009 Apr;41(4):399-406. doi: 10.1038/ng.364. Epub 2009 Mar 22.
3
Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation.羟嗪，一种第一代H(1)受体拮抗剂，抑制人醚-去极化相关基因（HERG）电流，并在一名患有HERG突变的患者中导致晕厥。
J Pharmacol Sci. 2008 Dec;108(4):462-71. doi: 10.1254/jphs.08178fp. Epub 2008 Dec 5.
4
Common candidate gene variants are associated with QT interval duration in the general population.常见的候选基因变异与普通人群的QT间期时长有关。
J Intern Med. 2009 Apr;265(4):448-58. doi: 10.1111/j.1365-2796.2008.02026.x. Epub 2009 Oct 25.
5
Molecular determinants of hERG channel block by terfenadine and cisapride.特非那定和西沙必利对人乙醚-a-去极化相关基因（hERG）通道阻滞的分子决定因素
J Pharmacol Sci. 2008 Nov;108(3):301-7. doi: 10.1254/jphs.08102fp. Epub 2008 Nov 6.
6
The human ERG1 channel polymorphism, K897T, creates a phosphorylation site that inhibits channel activity.人类ERG1通道多态性K897T产生了一个抑制通道活性的磷酸化位点。
Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14704-8. doi: 10.1073/pnas.0802250105. Epub 2008 Sep 12.
7
Identification of large gene deletions and duplications in KCNQ1 and KCNH2 in patients with long QT syndrome.长QT综合征患者中KCNQ1和KCNH2基因大片段缺失和重复的鉴定。
Heart Rhythm. 2008 Sep;5(9):1275-81. doi: 10.1016/j.hrthm.2008.05.033. Epub 2008 Jun 4.
8
Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels.药物与失活状态的结合对于与人醚-去-去相关基因通道的高亲和力结合是必要的，但并非充分条件。
Mol Pharmacol. 2008 Nov;74(5):1443-52. doi: 10.1124/mol.108.049056. Epub 2008 Aug 13.
9
hERG potassium channels and the structural basis of drug-induced arrhythmias.人乙醚-去极化激活的钾离子通道与药物诱导心律失常的结构基础
Chem Res Toxicol. 2008 May;21(5):1005-10. doi: 10.1021/tx800035b. Epub 2008 May 1.
10
The non-synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of KCNH2 (HERG).非同义编码的 IKr 通道变体 KCNH2-K897T 与心房颤动相关：基于 KCNH2（HERG）的系统性候选基因分析结果
Eur Heart J. 2008 Apr;29(7):907-14. doi: 10.1093/eurheartj/ehm619. Epub 2008 Jan 25.
Zotero 插件